Bristol-Myers reports no CVR payment due for Abraxane 2022 net sales of $909M

BRISTOL MYERS SQUIBB CO

2022 Abraxane net sales of $908,974,933 triggered no payment under Celgene CVR agreement.
Company notified trustee on Feb 23, 2023; no Net Sales Payment due per CVR terms.
CVR relates to Celgene acquisition from Nov 2019; future payments may be disclosed on BMS website.

item 8.01

BRISTOL MYERS SQUIBB CO filing history →

Source: SEC EDGAR

accession 0001140361-23-009050

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.